Navigation Links
Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Date:11/11/2008

ance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: the immunologic activity of HspE7 in treating CIN; that we identified an optimal dosing range for Phase 2 development and that our TLR3 agonist may have application in both therapeutic as well as prophylactic vaccines.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that immunologic activity of HspE7 may not treat CIN; the possibility that immunology responses may not be a predictor of clinical or therapeutic benefit; our need for capital; the outcomes of our clinical trials; the possibility that our drug candidate will not treat target diseases as intended; the possibility that we will not be successful in licensing our TLR3 agonist to other vaccine developers; risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candidate be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at '/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... biopharmaceutical company advancing patient care in critical areas, announced ... shares of common stock, and warrants to purchase up ... an offering price of $4.00 per share and $.01 ... price of $5.00, are exercisable immediately, and expire 5 ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument (Liquid ... Valves, Guages, Seals), Accessories, Services, End User (Biotechnology, ... provides a detailed overview of the major drivers, ... impacting the preparative and process chromatography market along ... and share analysis. , Full Copy of ...
(Date:12/24/2014)... SoundConnect’s 2015 ... introduce cutting edge communication technology, provide continued ... platform upgrades. This webinar series demonstrates online ... their quest to leverage web conferencing’s most ... SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our webinars ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... ROCKVILLE, Md., Nov. 26 Human Genome,Sciences, Inc. (Nasdaq: ... the,Piper Jaffray 19th Annual Health Care Conference will be ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ), A member of ... of the company on Wednesday, November 28, 2007 at ...
... Genta,Incorporated (Nasdaq: GNTA ) announced today ... Raymond P. Warrell, Jr., will provide a,company overview ... Capital,Markets 4th Annual Healthcare Conference. Genta,s presentation is ... at the New York Palace Hotel,New York, NY., ...
... Orthopedic Surgeons and Rheumatologists Performing More Procedures, ... US,Hyaluronic Acid (HA) Viscosupplementation Marketrack(TM) service, which,captures data ... groups provided more HA knee injections in Q3 ... in both groups, there are substantial,differences in the ...
Cached Biology Technology:Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference 2Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference 3Hyaluronic Acid Knee Procedures Grow 38% from Q3 2006 to Q3 2007 2
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... Lithosphere is now online. Locations studied include the ... Wet Mountains of Central Colorado, USA; the Basgo ... Utah, USA; Knight Inlet in the southwestern Coast ... shear zones in the western Canadian Shield of ...
... Genetic tests can now tell us whether we are ... asthma and a number of other conditions., Other genetic tests ... be harmed by side effects linked to your genetic code. ... illnesses in others will require that doctors have access to ...
... The forage grasses and other plants beef cattle ... University animal science researchers report that steers grazing on one ... growth, carcass and meat quality. The research can help ... are looking to add weight and value to their animals ...
Cached Biology News:Lithosphere interprets earth 2Lithosphere interprets earth 3Lithosphere interprets earth 4Lithosphere interprets earth 5Lithosphere interprets earth 6Lithosphere interprets earth 7Genetics in Medicine publishes special issue dedicated to genomics in electronic health records 2Genetics in Medicine publishes special issue dedicated to genomics in electronic health records 3Genetics in Medicine publishes special issue dedicated to genomics in electronic health records 4
Plasmid expressing the LacZ reporter gene....
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... These 2800mL PYREX Fernbach-style culture flasks ... of the flask bottom to achieve maximal ... have a large marking spot., A wide ... these bottles including:, Polypropylene colored caps ...
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
Biology Products: